TriPath closes Cytyc's lead on FDA nod
This article was originally published in Clinica
Executive Summary
TriPath Imaging has at last manage to close in on its major rival in the cervical cancer screening market, after gaining US FDA approval to expand labelling claims for its cervical cancer test.